博雅生物
(300294)
| 流通市值：126.26亿 | | | 总市值：126.26亿 |
| 流通股本：5.04亿 | | | 总股本：5.04亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 761,753,926.76 | 1,005,196,859.03 | 586,740,774.48 | 1,299,851,770.61 |
| 交易性金融资产 | 2,354,580,236.62 | 2,169,348,669.36 | 2,761,357,227.44 | 2,199,127,063.15 |
| 应收票据及应收账款 | 651,694,789.03 | 631,334,855.73 | 598,635,728 | 453,404,517.85 |
| 其中：应收票据 | 3,150,679 | 7,066,386.66 | 6,902,120.27 | 4,933,656.1 |
| 应收账款 | 648,544,110.03 | 624,268,469.07 | 591,733,607.73 | 448,470,861.75 |
| 应收款项融资 | 81,101,236.54 | 67,643,786.56 | 60,880,441.97 | 55,974,878.8 |
| 预付款项 | 20,433,465.48 | 13,873,462.38 | 14,540,699.25 | 13,623,534.65 |
| 其他应收款合计 | 88,700,959.69 | 88,391,412.02 | 39,962,909.55 | 39,809,915 |
| 存货 | 1,119,269,702 | 1,019,643,391.93 | 983,308,049.53 | 995,427,153.22 |
| 其他流动资产 | 36,999,645.23 | 2,504,986.7 | 2,048,428.15 | 1,131,298.76 |
| 流动资产合计 | 5,114,533,961.35 | 4,997,937,423.71 | 5,047,474,258.37 | 5,058,350,132.04 |
| 非流动资产: | | | | |
| 长期股权投资 | 39,096,418.09 | - | - | - |
| 其他非流动金融资产 | 92,160,703.96 | 88,283,118.69 | 95,365,746.4 | 81,094,746.4 |
| 投资性房地产 | 560,925.6 | 573,506.94 | 586,088.28 | 598,669.62 |
| 固定资产 | 693,745,322.4 | 799,548,672.6 | 813,997,581.07 | 837,410,357.02 |
| 在建工程 | 800,666,347.63 | 693,615,126.76 | 415,684,165.33 | 321,002,761.13 |
| 使用权资产 | 7,148,818.89 | 9,831,345.15 | 10,991,460.63 | 11,789,360.01 |
| 无形资产 | 663,590,625.06 | 739,689,314.57 | 763,666,052.71 | 773,275,862.44 |
| 开发支出 | 111,238,943.88 | 98,963,013.05 | 111,938,452.71 | 108,443,041.47 |
| 商誉 | 727,996,027.69 | 727,996,027.69 | 727,996,027.69 | 727,996,027.69 |
| 长期待摊费用 | 28,175,419.03 | 31,207,693.44 | 34,337,672.41 | 37,452,984.7 |
| 递延所得税资产 | 76,252,206.38 | 75,550,078.52 | 74,772,447.59 | 73,537,423.69 |
| 其他非流动资产 | 371,945,187.21 | 414,677,046 | 381,896,630.54 | 370,193,402.78 |
| 非流动资产合计 | 3,612,576,945.82 | 3,679,934,943.41 | 3,431,232,325.36 | 3,342,794,636.95 |
| 资产总计 | 8,727,110,907.17 | 8,677,872,367.12 | 8,478,706,583.73 | 8,401,144,768.99 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 521,649,453.74 | 506,195,524.42 | 312,432,828.87 | 357,623,076.65 |
| 其中：应付票据 | 257,302,261.12 | 201,958,062.88 | 226,291,379.96 | 207,704,840.99 |
| 应付账款 | 264,347,192.62 | 304,237,461.54 | 86,141,448.91 | 149,918,235.66 |
| 合同负债 | 5,733,246.86 | 6,369,931.09 | 6,353,655.13 | 4,076,548.97 |
| 应付职工薪酬 | 91,140,648.2 | 83,934,702.34 | 67,090,793.88 | 98,581,246.52 |
| 应交税费 | 13,731,693.11 | 37,975,329.28 | 49,985,877.92 | 27,965,410.99 |
| 其他应付款合计 | 282,859,471.18 | 258,478,871.85 | 255,212,344.92 | 256,128,209.46 |
| 一年内到期的非流动负债 | 2,551,790.45 | 4,049,817.45 | 4,644,904.09 | 5,333,163.12 |
| 其他流动负债 | 829,548.98 | 873,527.05 | 855,174.09 | 668,267.7 |
| 流动负债合计 | 918,495,852.52 | 897,877,703.48 | 696,575,578.9 | 750,375,923.41 |
| 非流动负债: | | | | |
| 长期借款 | 1,163,715.57 | - | - | - |
| 租赁负债 | 4,363,595.88 | 4,936,567.81 | 6,467,728.13 | 7,174,678.7 |
| 递延收益 | 17,855,658.35 | 18,893,694.86 | 18,504,435.54 | 19,507,084.56 |
| 递延所得税负债 | 112,783,321.07 | 126,009,384.79 | 130,474,708.35 | 136,324,307.6 |
| 非流动负债合计 | 136,166,290.87 | 149,839,647.46 | 155,446,872.02 | 163,006,070.86 |
| 负债合计 | 1,054,662,143.39 | 1,047,717,350.94 | 852,022,450.92 | 913,381,994.27 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 504,248,738 | 504,248,738 | 504,248,738 | 504,248,738 |
| 资本公积 | 4,062,997,016.14 | 4,062,997,016.14 | 4,062,997,016.14 | 4,062,997,016.14 |
| 其他综合收益 | -676,656.35 | -974,371.28 | 1,992,783.03 | 2,363,203.42 |
| 盈余公积 | 252,124,369 | 252,124,369 | 252,124,369 | 252,124,369 |
| 未分配利润 | 2,852,062,297.67 | 2,810,078,733.67 | 2,804,901,778.88 | 2,665,417,623.85 |
| 归属于母公司股东权益合计 | 7,670,755,764.46 | 7,628,474,485.53 | 7,626,264,685.05 | 7,487,150,950.41 |
| 少数股东权益 | 1,692,999.32 | 1,680,530.65 | 419,447.76 | 611,824.31 |
| 股东权益合计 | 7,672,448,763.78 | 7,630,155,016.18 | 7,626,684,132.81 | 7,487,762,774.72 |
| 负债和股东权益合计 | 8,727,110,907.17 | 8,677,872,367.12 | 8,478,706,583.73 | 8,401,144,768.99 |
| 公告日期 | 2025-10-28 | 2025-08-23 | 2025-04-25 | 2025-03-19 |
| 审计意见(境内) | | | | 标准无保留意见 |